[HTML][HTML] Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
[PDF][PDF] Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
A Rowan, D Schnidrig, R Thompson, F Byrne… - Cancer Cell, 2021 - academia.edu
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
L Au, E Hatipoglu, M Robert de Massy, K Litchfield… - 2021 - repository.cam.ac.uk
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
L Au, E Hatipoglu, MR de Massy, K Litchfield… - CANCER …, 2021 - kclpure.kcl.ac.uk
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
L Au, E Hatipoglu, M Robert de Massy, K Litchfield… - Cancer Cell, 2021 - discovery.ucl.ac.uk
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
[HTML][HTML] Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
L Au, E Hatipoglu, MR de Massy, K Litchfield… - Cancer Cell, 2021 - ncbi.nlm.nih.gov
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
L Au, E Hatipoglu, MR de Massy, K Litchfield… - Cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
[PDF][PDF] Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
A Rowan, D Schnidrig, R Thompson, F Byrne… - Cancer Cell, 2021 - researchgate.net
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
[引用][C] Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
L Au, E Hatipoglu, MR de Massy, K Litchfield, G Beattie… - Cancer Cell, 2021 - cir.nii.ac.jp
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
L Au, E Hatipoglu, M Robert de Massy, K Litchfield… - Cancer Cell, 2021 - europepmc.org
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …